Mundipharma international corporation limited, mundipharma medical company, and acrotech biopharma inc. enter agreement to transfer license of folotyn® (pralatrexate) in china to casi pharmaceuticals

Beijing , aug. 1, 2023 /prnewswire/ -- casi pharmaceuticals, inc. (nasdaq: casi), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the execution of an assignment agreement (the "agreement") with mundipharma international corporation limited ("micl"), mundipharma medical company ("mmco"), and acrotech biopharma inc. ("acrotech") for the commercialization of folotyn® (pralatrexate) in the people's republic of china ("china"). folotyn® (pralatrexate) is a dihydrofolate reductase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral t-cell lymphoma ("ptcl").
CASI Ratings Summary
CASI Quant Ranking